CMS, Medicare and obstructive sleep apnea

Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.
FDA approves first ever medication for obstructive sleep apnea — here's what that means
The US Food and Drug Administration has approved the first ever prescribed medicine for Obstructive Sleep Apnea. Read on to find out more information.
CMS confirms to CNBC Medicare plans can now cover Zepbound for sleep apnea
The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug
Medicare may cover Eli Lilly’s Zepbound for sleep apnea: Department of Health and Human Services agency
Both Novo Nordisk and Eli Lilly are studying their weight loss drugs to treat fatty liver disease, chronic kidney disease, sleep apnea and more. To be covered, these drugs would need to have late-stage trial results and then seek FDA approval for these uses.
Zepbound Approved for Obstructive Sleep Apnea in Patients With Obesity
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
Suffer from sleep apnea? The first FDA-approved medication could help
For about 25 million Americans who suffer from obstructive sleep apnea, there are various effective treatments such as CPAP breathing machines, surgery, a dental mouthpiece and even an implantable pac
FDA approves Zepbound for sleep apnea in obese adults
Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over
Medicare Expands Coverage of Eli Lilly’s Weight-Loss Drug
Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f
Zepbound can now be covered by Medicare
El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly expand access to the popular, yet costly treatment.
New imaging technique could transform obstructive sleep apnea diagnosis
Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent airway blockages during sleep, leading ...
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive ...
Everyday Health12d
FDA Approves First Medication for Obstructive Sleep Apnea
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...
Science Daily3d
Obstructive Sleep Apnea News
However, the machines tend to be ... May 30, 2024 — A new study demonstrates that when individuals with obstructive sleep apnea use their positive airway pressure machine more regularly ...
Daily Independent12h
Understanding the dangers of untreated sleep apnea
There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people with OSA don't sleep well, they are at a higher risk for motor vehicle ...
I Started Waking Up Hours Before My Alarm, So I Asked a Sleep Doctor What to Do
When I have sleep problems, it's usually not about struggling to fall asleep; I conk out pretty quickly once I get in bed.
The best sleep tech from CES 2025 so far — from brain bands to singing smart rings
From sleep apnea-fighting mattresses to smart rings that play lullabies, the best sleep tech from Day 1 of CES 2025 ...
Future Market Insights1d
Sleep Apnea Diagnostic Systems Industry to Nearly Double, Reaching USD 9.27 Billion by 2033 at a 6.8% of CAGR
The sleep apnea diagnostic systems market is expected to grow from US$ 4.81 billion in 2023 to US$ 9.27 billion by 2033, at a ...